CTOs on the Move

Harken Health

www.harkenhealth.com

 
Harken Health is a new kind of health care company that unites relationship-based primary care with a range of competitively priced insurance plan options. Our care approach is rooted in the values of a simpler time when the doctor-patient relationship mattered. Harken Health Care Teams are empowered with the time to listen and build authentic, compassionate, trusting relationships with members. Our model enables us to remove many of the barriers that often get in the way of delivering exceptional care. Strong relationships and a home base for primary care have been shown to improve patient satisfaction and lower overall medical ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Peter Vladimirov
Chief Technology Officer Profile

Similar Companies

MedAvante Inccvc

MedAvante Inccvc is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. MedAvante Inccvc is based in Trenton, NJ. You can find more information on MedAvante Inccvc at www.medavante.net

Nexgel

NEXGEL Advanced Hydrogel Solutions in a manufacturer of unique trans-dermal delivery system that was originally developed and FDA-approved for the Hospital Wound Care market, and is now being deployed against Consumer OTC, Rx, Medical Device and Cosmetic applications.

Teresian House

Teresian House is a Albany, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

First Health Group Corporation

First Health Group Corporation is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Assembly Biosciences

Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly`s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. We pride ourselves on creating a culture and work environment that is scientifically driven, ambitious, and collaborative. We encourage diversity of thought that leads to great innovation and are looking to add to our dynamic team great people who are driven to transform the lives of patients. We believe our Microbiome platform represents a best in class approach to developing biopharmaceutical agents from live biotherapeutic products. ABI-M201, our lead program in mildly to moderately active ulcerative colitis (UC), is currently in a phase 1b clinical trial. This program is part of a broader collaboration we established with Allergan in 2017 for gastrointestinal programs such as UC, Crohn`s disease and Irritable Bowel Syndromes with potential total development and commercial milestones of up to $2.8 billion. Our internal pipeline comprises first in class or best in class live microbial biotherapeutic approaches in areas such as oncology, immune mediated and metabolic disorders, and other areas of high medical need. Assembly is headquartered in Carmel, Indiana, while the R&D headquarters is in South San Francisco. The Company also has a microbiome manufacturing facility in Groton, CT, and offices in China.